Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 15/2014

01-10-2014 | R&D Insight Report

Suvorexant: First Global Approval

Author: Lily P. H. Yang

Published in: Drugs | Issue 15/2014

Login to get access

Abstract

Suvorexant (Belsomra®), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neurons in the lateral hypothalamus regulate wakefulness by signalling through orexin receptors. Blockade of orexin receptors is known to promote sleep. Suvorexant was approved in the US in August 2014 for the treatment of adults with sleep onset and/or sleep maintenance insomnia. The drug is also preregistration in Japan, with approval submissions planned for other countries worldwide for this indication. This article summarizes the milestones in the development of suvorexant leading to this first approval for insomnia.
Literature
1.
2.
Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders: rationale for development and current status. CNS Drugs. 2013;27(2):83–90.PubMedCrossRef
3.
4.
5.
Merck & Co. Merck receives Complete Response Letter for suvorexant, Merck’s investigational medicine for insomnia [media release]. 1 July 2013. http://​www.​merck.​com.
6.
7.
Connor K, Budd K, Snavely D, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1) [abstract no. O324]. J Sleep Res. 2012;21(Suppl 1):97.
8.
Ivgy-May N, Leibensperger H, Froman S, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #2) [abstract no. P988]. J Sleep Res. 2012;21(Suppl 1):351–2.
9.
Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–71.PubMedCrossRef
10.
Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265–74.PubMedCrossRef
11.
Merck & Co. Merck announces full-year and fourth-quarter 2012 financial results. 2012.
12.
Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by suvorexant: a novel dual orexin receptor antagonist. J Neurogenet. 2011;25(1–2):52–61.PubMedCrossRef
13.
14.
Sun H, Kennedy D, Lewis N, et al. The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305), a dual orexin receptor antagonist, in healthy male subjects [abstract no. PI-59]. Clin Pharmacol Ther. 2012;91(Suppl 1):S29.
15.
Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259–67.PubMedPubMedCentral
16.
Sun H, Yee KL, Khalilieh S, et al. Phase 1 safety, pharmacokinetics, and pharmacodynamics of the orexin receptor antagonist suvorexant administered with alcohol or paroxetine [abstract no. 0650]. Sleep. 2013;36(Suppl):A224.
17.
Herring WJ, Ivgy-May N, Connor KM, et al. Effect of suvorexant, an orexin receptor antagonist, on patient-reported outcomes in patients with primary insomnia: integrated results from two phase-3 trials [abstract no. 0648]. Sleep. 2013;36(Suppl):A223.
18.
Hisada S, Kikuchi M, Takahashi K, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase III study (P028) [abstract no. 0649]. Sleep. 2013;36(Suppl):A224.
19.
Connor KM, Matzura-Wolfe D, Zhang Y, et al. Safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: integrated phase 3 results [abstract no. 0647]. Sleep. 2013;36(Suppl):A223.
20.
Vermeeren A, Vuurman E, Van Oers A, et al. Effects of suvorexant, an orexin receptor antagonist, on next day driving performance in healthy volunteers [abstract no. W11]. In: 51st Annual Meeting of the American College of Neuropsychopharmacology; 2–6 Dec 2012; Hollywood (FL).
21.
Uemura N, McCrea J, Sun H, et al. Effects of supratherapeutic and therapeutic doses of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects [abstract no. 0645]. Sleep. 2013;36(Suppl):A222.
22.
Troyer M, Uemura N, McCrea J, et al. Respiratory safety of the orexin receptor antagonist suvorexant during sleep in patients with compromised respiratory function and in healthy subjects [abstract no. P5.293]. Neurology. 2014;82(10 Suppl 1).
Metadata
Title
Suvorexant: First Global Approval
Author
Lily P. H. Yang
Publication date
01-10-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 15/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0294-5

Other articles of this Issue 15/2014

Drugs 15/2014 Go to the issue

Erratum

Erratum to: Idelalisib: First Global Approval

Adis Drug Evaluation

Dabigatran Etexilate: A Review of Its Use in the Treatment of Acute Venous Thromboembolism and Prevention of Venous Thromboembolism Recurrence

Therapy in Practice

Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide

R&D Insight Report

Oritavancin: First Global Approval

R&D Insight Report

Eliglustat: First Global Approval

Adis Drug Evaluation

Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer